XIN LI, PhD
Picture
XIN LI, PhD
Instructor
Positions
- Instructor
-
Pharmacology & Chemical Biology
Baylor College of Medicine
Houston, Texas United States
- Associate member
-
Baylor College of Medicine
Dan L Duncan Comprehensive Cancer Center
Houston, Texas United States
Addresses
- Baylor College of Medicine (Office)
-
1 Baylor Plaza
Alkek building, N510
Houston, TX 77030
United States
Education
- Postdoctoral Fellowship at Baylor College of Medicine
- 04/2023 - Houston, Texas United States
- Postdoctoral Fellowship at University of Houston
- 09/2019 - Houston, Texas United States
- Postdoctoral Fellowship at Texas Tech University Health Sciences Center
- 09/2017 - Amarillo, Texas United States
- PhD from Shandong University
- 06/2016 - Jinan, China
Professional Interests
- Drug Discovery, Medicinal Chemistry and Chemical Biology
Professional Statement
I am dedicated to the field of medicinal chemistry and drug discovery, driven by a passion for combating human diseases and improving human health.My academic training encompasses rational and computer-aided drug design, organic chemistry, and drug evaluation/action of mechanism studies with a number of techniques, including recombinant protein expression and purification, various biochemical (such as UV/fluorescence-based and Alpha/ITC/BLI) assays, cell culture, Western blot, CHIP-qPCR, and gene set enrichment analysis. I have got a full set of primary academic trainings in medicinal chemistry and drug discovery.
I have over 10 years of wet lab research experience in medicinal chemistry and drug discovery, and have discovered and developed several kinds of protein inhibitors/degraders (published) including novel antibacterial macrolides targeting bacterial ribosome and cinnamaldehyde analogs targeting FtsZ (2010-2016), anticancer agents targeting MDM2/MDM4 (2016-2019), anticancer agents targeting P300/CBP, AHD and ENL (2019-), and novel antiviral agents against flaviviruses, coronaviruses and noroviruses (2019-). I have gained a wealth of experience, especially in the anti-infective and anticancer drug discovery areas.
These academic training and research experience have provided me with a strong background in the discovery and development of novel chemical probes or drug leads, which could be used for the fundamental biology study or for the further drug development.
Websites
Selected Publications
- Xin Li, Yuan Yao, Fangrui Wu, Yongcheng Song "A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth." J Hematol Oncol. 2022 Apr 8;2022(15):41. Pubmed PMID: 35395864
- Md Ashraf-Uz-Zaman #, Xin Li #, Yuan Yao #, Chandra Bhushan Mishra, Bala Krishna Moku, and Yongcheng Song "Quinazolinone Compounds Have Potent Antiviral Activity against Zika and Dengue Virus." J Med Chem. 2023 Jul 28; Pubmed PMID: 37506506
- Xin Li, Yongcheng Song "Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy." J Hematol Oncol. 2020 May 13;13:50. Pubmed PMID: 32404196
- Xin Li, Yongcheng Song "Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins." J Hematol Oncol. 2021 Apr 6;14(1):56. Pubmed PMID: 33823889
- Xin Li #, Yongcheng Song # "Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review." Eur J Med Chem. 2023 Aug 31;260:115772. Pubmed PMID: 37659195
- Shenyou Nie*, Fangrui Wu*, Jingyu Wu*, Xin Li*, Chao Zhou, Yuan Yao, Yongcheng Song "Structure-activity relationship and antitumor activity of 1, 4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP." Eur J Med Chem. 2022;237(5):114407. Pubmed PMID: 35512565
- Fangrui Wu, Shenyou Nie, Yuan Yao, Tong Huo, Xin Li, Xiaowei Wu, Jidong Zhao, Yi-Lun Lin, Yinjie Zhang, Qianxing Mo, Yongcheng Song "Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth." Theranostics. 2021;11(17):8172-8184. Pubmed PMID: 34373735
- Shenyou Nie, Jidong Zhao, Xiaowei Wu, Yuan Yao, Fangrui Wu, Yi-Lun Lin, Xin Li, Alexander R Kneubehl, Megan B Vogt, Rebecca Rico-Hesse, Yongcheng Song "Synthesis, structure-activity relationship and antiviral activity of indole-containing inhibitors of Flavivirus NS2B-NS3 protease." Eur J Med Chem. 2021 Nov 5;225:113767. Pubmed PMID: 34450494
- Xin Li *, Xiaowei Wu *, Shenyou Nie, Jidong Zhao, Yuan Yao, Fangrui Wu, Chandra Bhushan Mishra, Md Ashraf-Uz-Zaman, Bala Krishna Moku, Yongcheng Song "Discovery, Structure–Activity Relationship and In Vitro Anticancer Activity of Small-Molecule Inhibitors of the Protein–Protein Interactions between AF9/ENL and AF4 or DOT1L." Cancers. 2023 Nov 3;15(21):5283. Pubmed PMID: 37958457
- Xin Li #, Yongcheng Song # "Targeting SARS-CoV-2 nonstructural protein 3: function, structure, inhibition, and perspective in drug discovery." Drug Discov Today. 2023 Nov 15;29(1):103832. Pubmed PMID: 37977285
- Md Ashraf-Uz-Zaman *, Teck Khiang Chua *, Xin Li *, Yuan Yao, Bala Krishna Moku, Chandra Bhushan Mishra, Vasanthi Avadhanula, Pedro A. Piedra, and Yongcheng Song "Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease." ACS Infect Dis. 2024 Jan 8;10(2):715-731. Pubmed PMID: 38192109
Funding
- SynthX/Duncan Cancer Center Seed Award Grant funding from SynthX Center and the Duncan Cancer Center
Skills
- Drug design/synthesis, Natural product modification
- Docking, Molecular modeling, Virtual screening
- Drug-screening/-evaluation related biophysical/cellular study (Fluorescence polarization, AlphaLISA/Screen, M/XTT, Western blotting, ChIP, RT-qPCR...
Log In to edit your profile
